# A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy

> **NCT05559775** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Gastrointestinal Cancer

## Interventions

- **DRUG:** Pemigatinib Pill

## Key facts

- **NCT ID:** NCT05559775
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-10
- **Primary completion:** 2024-08-10
- **Final completion:** 2025-08-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05559775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05559775, "A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05559775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*